Investing.com -- Capricor Therapeutics Inc (NASDAQ: CAPR) stock tumbled 20.4% following news that two top FDA officials overseeing cell and gene therapies have been placed on administrative leave.

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...

Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week ...

A 19-year-old severe thalassemia patient has recently become China's first successful case cured through cell and gene therapy at Nansha Hospital of Guangzhou First Municipal People's Hospital. This ...

The biotech plans to use one-year follow-up data from the Phase II/III trial to support a biologics license application for OCU410ST in 2027.

By fine-tuning polishing conditions, scientists attain high titers of infectious lentiviral particles during purification.

Xie Zhen's team from Tsinghua University published a research article titled "SPECIFIC: A systematic framework for ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

The FDA announced a new fast-track approval program for domestic drug developers for projects that are national priorities.